Regulus Therapeutics Inc. (NASDAQ:RGLS) is set to release its earnings data after the market closes on Tuesday, November 7th. Analysts expect Regulus Therapeutics to post earnings of ($0.17) per share for the quarter.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. On average, analysts expect Regulus Therapeutics to post $-0.97 EPS for the current fiscal year and $-0.38 EPS for the next fiscal year.

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) traded up 1.9900% during mid-day trading on Wednesday, reaching $1.0199. 62,800 shares of the company’s stock were exchanged. The firm’s market capitalization is $105.85 million. Regulus Therapeutics Inc. has a one year low of $0.79 and a one year high of $3.38. The stock has a 50-day moving average of $1.27 and a 200 day moving average of $1.21.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/11/01/regulus-therapeutics-inc-rgls-set-to-announce-earnings-on-tuesday.html.

RGLS has been the subject of several recent research reports. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research report on Wednesday, July 12th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. Chardan Capital lowered Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Finally, Wedbush reissued an “ourperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a research report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. Regulus Therapeutics has a consensus rating of “Hold” and an average target price of $3.67.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.